



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|--|--|
| Summary for ARTG Entry: | 100128 | Xue Fu Zhu Yu Tang a.k.a. Persica & Cnidium Blood Moving Formula |
| ARTG entry for | Medicine Listed | |
| Sponsor | Sun Herbal Pty Ltd | |
| Postal Address | Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia | |
| ARTG Start Date | 10/03/2004 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

This medicine contains a preparation of Carthamus tinctorius flower for oral use. From 1 July 2011 all Listed Medicines containing preparations of Carthamus tinctorius flower for oral use must include the label advisory statement 'Do not use if pregnant or likely to become pregnant'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Xue Fu Zhu Yu Tang a.k.a. Persica & Cnidium Blood Moving Formula

| | | | |
|---------------------|-------------------------|-----------------------|-----------|
| Product Type | Single Medicine Product | Effective Date | 1/06/2018 |
|---------------------|-------------------------|-----------------------|-----------|

Permitted Indications

Traditionally used in Chinese medicine to invigorate/activate Blood

Traditionally used in Chinese medicine to eliminate/reduce/remove/resolve/dissipate blood-stasis

Traditionally used in Chinese medicine to increase/augment/generate/promote/strengthen qi

Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not use if pregnant or likely to become pregnant (or words to that effect)

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

| | |
|---|----------------|
| Achyranthes bidentata root Extract dry concentrate | 28.8 mg |
| Equivalent: Achyranthes bidentata (Dry) | 172.8 mg |
| Angelica polymorpha root Extract dry concentrate | 21.6 mg |
| Equivalent: Angelica polymorpha (Dry) | 129.6 mg |
| Bupleurum falcatum root Extract dry concentrate | 21.6 mg |
| Equivalent: Bupleurum falcatum (Dry) | 129.6 mg |
| Carthamus tinctorius flower Extract dry concentrate | 21.6 mg |
| Equivalent: Carthamus tinctorius (Dry) | 129.6 mg |
| Citrus aurantium fruit Extract dry concentrate | 21.6 mg |
| Equivalent: Citrus aurantium (Dry) | 129.6 mg |
| Glycyrrhiza uralensis root Extract dry concentrate | 12 mg |
| Equivalent: Glycyrrhiza uralensis (Dry) | 72 mg |
| Ligusticum striatum root Extract dry concentrate | 21.6 mg |
| Equivalent: Ligusticum striatum (Dry) | 129.6 mg |
| Paeonia lactiflora root Extract dry concentrate | 21.6 mg |
| Equivalent: Paeonia lactiflora (Dry) | 129.6 mg |
| Paeonia obovata root Extract dry concentrate | 21.6 mg |
| Equivalent: Paeonia obovata (Dry) | 129.6 mg |
| Platycodon grandiflorus root Extract dry concentrate | 14.4 mg |
| Equivalent: Platycodon grandiflorus (Dry) | 86.4 mg |
| Prunus persica seed Extract dry concentrate | 21.6 mg |
| Equivalent: Prunus persica (Dry) | 129.6 mg |
| Rehmannia glutinosa root Extract dry concentrate | 36 mg |
| Equivalent: Rehmannia glutinosa (Dry) | 216 mg |
| Salvia miltiorrhiza root Extract dry concentrate | 36 mg |
| Equivalent: Salvia miltiorrhiza (Dry) | 216 mg |

Other Ingredients (Excipients)

hydrolysed gelatin

titanium dioxide

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.